Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Fennec Pharmaceuticals (FENC) over the last 5 years, with Sep 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Non-Current Assets rose 234.41% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 234.41%. This contributed to the annual value of $822,000 for FY2024, which is 13600.00% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Non-Current Assets of $3.2 million as of Q3 2025, which was down 21.68% from $4.1 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Non-Current Assets' 5-year high stood at $4.1 million during Q2 2025, with a 5-year trough of $6,000 in Q4 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $956,000 (2024), whereas its average is $1.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first slumped by 97.16% in 2023, then skyrocketed by 13,600.00% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Non-Current Assets (Quarterly) stood at $35,000 in 2021, then soared by 654.29% to $211,000 in 2022, then plummeted by 97.16% to $6,000 in 2023, then spiked by 13,600.00% to $822,000 in 2024, then skyrocketed by 234.41% to $3.2 million in 2025.
  • Its Non-Current Assets stands at $3.2 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.4 million for Q1 2025.